drug delivery | GenomeWeb

drug delivery

This article has been updated to clarify details regarding Traversa Therapeutics' bankruptcy proceedings.

Roughly one year after securing €5 million ($6.5 million) in venture capital funding, Spanish oligonucleotide drug developer nLife Therapeutics has set its sights on initiating non-human primate testing of its core intranasal delivery technology, which it hopes will spur licensin

Less than a year after Traversa Therapeutics declared bankruptcy, the company's founders are making another run at the RNAi drugs space in the form of startup Solstice Biologics, which announced this week that it has raised $18 million in a Series A round of financing.

By Doug Macron
The National Institutes of Health last month handed out nearly $1.3 million in grant funding to support four research projects focused on developing siRNA-delivery technologies.

Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.

Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.

By Doug Macron
About a year and a half after its founding, siRNA delivery firm Qualiber has secured a $30,000 low-interest loan from the North Carolina Biotechnology Center to help it with non-scientific startup activities.

Molecular Templates is developing molecules called Engineered Toxin Bodies, or ETBs, which are derived from bacterial toxins that have been engineered with a unique targeting domain and designed for reduced immunogenicity, while retaining the biological properties of the parent scaffold.

The deals suggest that big pharma remains interested in the gene-silencing technology despite recent pullbacks in the sector, which have raised concerns among industry watchers.

The application specifically relates to Marina's Smarticles technology, which it acquired from Novosom last summer.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.